OakChart

Universe Pharmaceuticals INC

UPCHealthcare·Drug Manufacturers - Specialty & Generic·China·Nano·NASD·Nov 11 • 12:40 PM ET

1.54-0.00 (-0.32%)
2026-11-11 18:48 CET
Market cap
7.79 USD m
Revenue, TTM
17.74 USD m
Net income, TTM
-1.94 USD m
Free cash flow, TTM
-12.39 USD m
EPS diluted, TTM
-3.45
P/E
-
Compare

Price

UPC against its 20, 50 and 200-day averages
2050200
5.0010.0015.0027.6M55.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26UPCclose 1.5520-day 2.5150-day 3.67200-day 3.711.5552w high

91.4% under the 52-week high of 17.96 on 29 Jun 2026. 52-week low 1.33 on 6 Nov 2026. Last 15 sessions, 250.4% high to low

Profile

UPC
52-week range, 1% of the way up
1.3317.96

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Employees216
IPOMar 23, 2021
Beta1.83
ATR, 14d0.35
Rel volume0.06
Short float7.77%
Insider own89.18%
Inst own2.19%

Snapshot

6 groups

Valuation

Index-
Market Cap7.76M
Enterprise Value-11.74M
Income-1.94M
Sales17.74M
Book/sh98.78
Cash/sh5.78
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees216
IPOMar 23, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S0.44
P/B0.02
P/C0.27
P/FCF-
EV/EBITDA-
EV/Sales-0.66
Quick Ratio3.75
Current Ratio4.05
Debt/Eq0.17
LT Debt/Eq0.04
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.45
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y82.27% -
Sales past 3/5Y-23.66% -10.27%
EPS Y/Y TTM-100.01%
Sales Y/Y TTM-8.04%
EPS Q/Q70.78%
Sales Q/Q-1.28%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own89.18%
Insider Trans0.00%
Inst Own2.19%
Inst Trans87.00%
ROA-2.55%
ROE-3.50%
ROIC-3.36%
Gross Margin35.86%
Oper. Margin-11.78%
Profit Margin-10.95%
SMA20-38.56%
SMA50-57.85%
SMA200-58.32%
Trades-

Technical

Shs Outstand0.56M
Shs Float0.54M
Short Float7.77%
Short Ratio0.24
Short Interest0.04M
52W High17.96 -91.40%
52W Low1.33 16.17%
Volatility11.78% 17.10%
ATR (14)0.35
RSI (14)26.94
Beta1.83
Rel Volume0.06
Avg Volume176.29K
Volume5,984

Performance

Perf Week5.10%
Perf Month-63.82%
Perf Quarter-73.68%
Perf Half Y-42.13%
Perf YTD-59.45%
Perf Year-57.08%
Perf 3Y-99.76%
Perf 5Y-99.98%
Perf 10Y-
Recom-
Target Price-
Prev Close1.55
Price1.54
Change %-0.32%

Peers

Mkt cap
TickerCompanyMkt cap
SXTCChina SXT Pharmaceuticals Inc2.04M
CPHIChina Pharma Holdings Inc22.53M
RGCRegencell Bioscience Holdings Ltd2.75B
ZYBTZhengye Biotechnology Holding Ltd45.19M
HKPDCellyan Biotechnology Co Ltd4.04M
ZCMDZhongchao Inc4.30M
ITOCiTonic Holdings Ltd14.59M
WOKWork Medical Technology Group Ltd5.94M
AHGAkso Health Group ADR1.16B
ZJYLJin Medical International Ltd721.37M

News

latest 14 of 96
  • Universe Pharmaceuticals Shares Rise 22.6% Premarket With No New Catalyst Identified (InvestorsHub) +11.71%
  • UPC Stock Surges 288% After Hours Whats Driving The Rally? (Stocktwits) +311.49%
  • Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio (GlobeNewswire)
  • Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure (GlobeNewswire) -19.61%
  • Universe Pharmaceuticals to conduct share consolidation (SeekingAlpha) -9.18%
  • Loading…
  • Universe Pharmaceuticals INC Announces Share Consolidation (GlobeNewswire)
  • Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report (GlobeNewswire) -6.13%
  • Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request (GlobeNewswire) -35.34%
  • Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC) (GlobeNewswire) -15.94% -7.76%
  • Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering (GlobeNewswire) -59.29%
  • Universe Pharmaceuticals INC Announces Share Consolidation (GlobeNewswire) -15.99%
  • Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +5.48%
  • Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024 (GlobeNewswire) -13.83% -13.95%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual1303.3441294.5241295.7121873.656-1446.048-653527.671-376176.617-8.055
Period20182019202020212022202320242025
EPS, quarterly
Period
Sales, annual28.51433.22930.70447.98240.14332.30923.02417.859
Period20182019202020212022202320242025
Sales, quarterly
Period
Shares, annual0.0060.0060.0060.0060.006000.563
Period20182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue17.7417.8623.0232.3140.1447.9830.7033.2328.51
Cost of Goods Sold Incl. D&A11.3811.9817.2022.2318.4622.8516.8120.0515.36
Gross Profit6.365.885.8210.0821.6925.1413.8913.1813.15
Selling, General and Administrative Excl. Other8.448.8013.6013.8628.9211.323.483.333.39
Research and Development0.660.502.994.827.625.450.570.600.76
Other Operating Expense0.010.000.250.180.210.220.160.100.10
Operating Income-2.09-2.92-8.02-3.97-7.4413.5910.259.759.66
Interest Expense0.230.230.280.160.160.100.120.130.16
Unusual Expense0.480.480.000.000.000.000.000.000.00
Net Income Before Taxes-2.01-3.74-8.15-4.36-8.0213.6510.089.639.50
Income Taxes0.000.000.612.250.752.362.542.101.92
Consolidated Net Income-1.94-3.67-8.73-6.58-8.7411.327.567.557.60
Net Income From Continuing Operations-1.94-3.67-8.73-6.58-8.7411.327.567.557.60
Net Income-1.94-3.67-8.73-6.58-8.7411.327.567.557.60
EPS (Recurring)-2.85-7.32-376,176.62-653,527.67-1,446.051,873.651,295.701,294.541,303.36
EPS (Basic, Before Extraordinaries)-3.45-8.05-376,176.62-653,527.67-1,446.051,873.661,295.711,294.521,303.34
EPS (Diluted)-3.45-8.05-376,176.62-653,527.67-1,446.051,873.661,295.711,294.521,303.34
EBITDA-1.61-2.40-7.53-3.46-6.9014.0410.6610.1710.11
Non-Operating Income (Expense)0.79-0.110.15-0.24-0.420.16-0.050.000.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Price To Earnings Ratio-----2,847.54---
Price To Sales Ratio0.090.110.000.000.311.12---
Gross Margin35.8632.9325.2931.1954.0252.3845.2439.6746.12
Operating Margin-11.78-16.33-34.83-12.28-18.5328.3233.3929.3533.87
Net Margin-10.95-20.56-37.90-20.37-21.7623.5924.6222.7326.66
Shares Outstanding0.560.560.000.000.010.010.010.010.01
Market Capitalization7.797.793,461.772,078.2044,239.50193,401.00184,788.00--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue9.048.719.1510.1412.8813.8418.4715.94
Cost of Goods Sold Incl. D&A5.815.575.997.569.649.7812.457.89
Gross Profit3.233.143.162.583.244.066.018.05
Selling, General and Administrative Excl. Other4.723.735.498.674.937.635.8018.06
Research and Development0.090.570.102.920.072.572.257.49
Other Operating Expense0.010.000.000.190.060.110.070.13
Operating Income-1.50-0.59-2.33-6.28-1.74-3.680.15-10.14
Interest Expense0.130.100.130.140.140.080.070.07
Unusual Expense0.000.480.00-7.627.620.000.000.00
Net Income Before Taxes-1.55-0.45-3.284.28-12.44-4.140.26-11.33
Income Taxes0.000.000.00-0.060.671.340.97-0.83
Consolidated Net Income-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
Net Income From Continuing Operations-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
Net Income-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
EPS (Recurring)-2.76-0.09-9.44-13,406.14-1,278.54-901.68-118.42-1,732.68
EPS (Basic, Before Extraordinaries)-2.76-0.69-9.4461,205.58-2,156.04-901.68-118.40-1,732.68
EPS (Diluted)-2.76-0.69-9.4461,205.58-2,156.04-901.68-118.40-1,732.68
EBITDA-1.27-0.34-2.06-6.04-1.49-3.430.41-9.90
Non-Operating Income (Expense)0.070.72-0.833.09-2.94-0.380.18-1.12
Price To Sales Ratio0.090.130.070.000.300.110.370.31
Gross Margin35.7036.0334.5725.4325.1829.3632.5750.52
Operating Margin-16.60-6.77-25.42-61.93-13.51-26.560.81-63.61
Net Margin-17.21-4.45-35.8943.14-101.68-39.36-3.87-65.67
Shares Outstanding0.560.560.560.000.010.010.010.01
Market Capitalization7.792.370.893,461.774,790.802,078.2045,570.6044,239.50

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments33.5929.505.2918.8621.8010.063.186.19
Short Term Receivables13.1918.5713.0015.1815.8110.876.427.64
Inventories4.682.723.522.225.201.912.628.12
Other Current Assets2.140.853.465.247.670.000.020.01
Total Current Assets53.6051.6425.2741.5150.4822.8412.2321.96
Net Property, Plant & Equipment14.7015.3414.9915.8317.874.434.575.08
Total Investments and Advances0.700.710.690.700.740.730.700.73
Intangible Assets0.300.260.150.160.180.170.170.18
Deferred Tax Assets-0.000.601.350.870.190.170.14
Other Assets0.000.000.040.000.000.440.000.00
Total Assets69.3067.9541.7259.5470.1428.8017.8428.08
Short Term Debt Incl. Current Port. of LT Debt9.265.865.483.944.332.652.522.62
Accounts Payable1.674.914.593.085.312.691.942.94
Income Tax Payable-1.020.430.171.101.330.550.89
Other Current Liabilities2.258.523.255.920.461.330.4411.94
Total Current Liabilities13.1720.3113.7513.1011.218.005.4518.40
Long Term Debt0.002.140.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities13.1722.4513.7513.1011.218.005.4518.40
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity56.1345.5027.9746.4458.9320.8012.389.68
Total Shareholders Equity56.1345.5027.9746.4458.9320.8012.389.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity56.1345.5027.9746.4458.9320.8012.389.68
Total Liabilities & Stockholders Equity69.3067.9541.7259.5470.1428.8017.8428.08
Book Value Per Share99.64636,701.572,768,408.277,687.009,754.653,566.212,122.981,659.70
Tangible Book Value Per Share99.11633,023.242,753,701.847,660.949,725.113,536.252,093.561,628.23
Full-Time Employees21622522522426356--
Price to Book Ratio0.0219.9643.84158.76546.94607.57--
Return on Assets-5.35-14.40-13.00-13.4722.8832.4132.89-
Return on Equity-7.23-20.53-17.69-16.5828.3945.5568.45-
Return on Invested Capital-6.54-18.32-23.53-18.8119.2136.3360.9878.53
Quick Ratio3.712.411.583.004.042.621.760.75
Current Ratio4.072.541.843.174.502.852.241.19

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1.94-3.67-8.73-6.58-8.7411.327.567.557.60
Depreciation0.480.520.490.510.530.450.410.420.45
Other Funds (Non Cash)0.370.370.19-0.050.44-0.230.020.11-0.09
Funds from Operations-1.09-2.78-7.45-4.55-8.3710.877.988.047.99
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.82-2.27-2.065.676.59-12.69-1.875.16-3.53
Income Taxes Payable0.54-0.320.550.28-0.90-0.300.73-0.320.44
Cash from Operating Activities-11.91-5.05-9.511.12-1.78-1.826.1213.204.46
Capital Expenditures-0.54-0.35-0.36-0.04-0.09-13.53-0.05-0.09-0.15
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.010.000.000.000.000.000.000.00
Purchase or Sale of Investments-1.490.000.000.000.00-13.530.000.000.00
Purchase of Investments-1.490.000.000.000.00-15.330.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.001.800.000.000.00
Other Uses0.000.000.000.00-3.810.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.02-0.34-0.36-0.04-3.91-27.06-0.05-0.09-0.15
Cash Dividends Paid0.000.000.000.000.000.000.00-16.01-3.06
Change in Capital Stock-0.0015.0025.000.000.0028.750.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-0.0015.0025.000.000.0028.750.000.000.00
Proceedsfrom Stock Options-0.0015.0025.000.000.0028.750.000.000.00
Issuance or Reduction of Debt, Net-5.42-5.278.95-1.393.320.620.910.00-1.85
Change in Long Term Debt--0.000.000.000.000.000.000.00
Issuance of Long Term Debt--0.000.000.000.000.000.000.00
Reduction of Long Term Debt--0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-2.79-0.440.000.00
Other Financing Activities Uses0.000.000.000.000.00-2.79-0.440.000.00
Cash from Financing Activities-6.829.7333.95-1.393.3226.580.47-16.00-4.91
Exchange Rate Effect1.04-0.240.13-0.11-0.460.550.35-0.13-0.19
Net Change in Cash-19.714.0924.21-0.43-2.84-1.746.88-3.01-0.79
Free Cash Flow-12.39-5.32-9.751.07-1.88-15.356.0613.124.31
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow---0.01-----
Deferred Taxes & Investment Tax Credit-0.000.611.57-0.61-0.67-0.01-0.040.02

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments29.0533.5947.2729.5011.3918.50
Short Term Receivables20.4613.1913.5318.5714.3810.73
Inventories3.984.684.192.723.763.52
Other Current Assets1.722.140.040.854.004.05
Total Current Assets55.2153.6065.0351.6433.5336.81
Net Property, Plant & Equipment15.2214.7014.6915.3414.9614.99
Total Investments and Advances0.720.700.690.710.690.69
Intangible Assets0.310.300.270.260.150.15
Deferred Tax Assets---0.000.000.66
Other Assets0.000.000.000.000.100.00
Total Assets71.4769.3080.6767.9549.4353.29
Short Term Debt Incl. Current Port. of LT Debt7.389.265.665.864.435.48
Accounts Payable3.751.677.404.917.764.59
Income Tax Payable0.66-0.121.020.170.43
Other Current Liabilities1.862.2510.238.528.243.25
Total Current Liabilities13.6513.1723.4220.3120.6113.75
Long Term Debt2.170.002.072.142.080.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities15.8213.1725.4822.4522.6913.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity55.6556.1355.1845.5026.7439.53
Total Shareholders Equity55.6556.1355.1845.5026.7439.53
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity55.6556.1355.1845.5026.7439.53
Total Liabilities & Stockholders Equity71.4769.3080.6767.9549.4353.29
Book Value Per Share98.7899.6497.96636,701.574,401.146,543.34
Tangible Book Value Per Share98.2399.1197.49633,023.244,376.856,518.75
Price to Book Ratio0.020.040.5619.96120.4943.84
Return on Assets-2.55-5.351.67-14.40-30.97-10.92
Return on Equity-3.50-7.232.66-20.53-50.22-14.34
Return on Invested Capital-2.69-0.69-5.749.18-45.46-13.78
Quick Ratio3.753.712.602.411.442.42
Current Ratio4.054.072.782.541.632.68

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-1.55-0.39-3.284.37-13.10-5.45
Depreciation0.230.250.270.240.250.25
Other Funds (Non Cash)0.000.370.00-10.2310.41-0.24
Funds from Operations-1.320.23-3.02-5.67-1.78-5.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.97-7.845.58-1.40-0.651.67
Income Taxes Payable-0.010.55-0.870.82-0.270.13
Cash from Operating Activities-4.30-7.612.56-7.08-2.43-3.64
Capital Expenditures-0.32-0.21-0.13-0.30-0.07-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.010.000.000.000.00
Purchase or Sale of Investments-1.490.000.000.000.000.00
Purchase of Investments-1.490.000.000.31-0.310.00
Sale Or Maturity of Investments0.000.000.00-0.310.310.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.81-0.21-0.13-0.29-0.07-0.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-0.0015.0025.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.0015.0025.000.000.00
Proceedsfrom Stock Options0.00-0.0015.0025.000.000.00
Issuance or Reduction of Debt, Net-0.15-6.671.402.896.07-3.47
Change in Long Term Debt-----0.00
Issuance of Long Term Debt-----0.00
Reduction of Long Term Debt-----0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.15-6.6716.4027.896.07-3.47
Exchange Rate Effect0.230.81-1.050.120.01-0.48
Net Change in Cash-6.03-13.6817.7820.643.58-7.63
Free Cash Flow-4.61-7.782.46-7.26-2.50-3.68
Price to Free Cash Flow-----3.09

Revenue breakdown

Revenue From Sales Of Selfmanufactured TCMDProducts2024: 14.03B 2025: 13.26B
Revenue From Sales Of Thirdparty Products2024: 9.00B 2025: 4.60B
China2024: 23.02B 2025: 17.86B
Total Pharmaceutical Preparations revenue2024: 23.02B 2025: 17.86B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.77%0.0M0.5M804.59K
2026-10-155.61%0.0M0.5M766.28K
2026-09-308.12%0.0M0.5M890.39K
2026-09-1514.05%0.1M0.5M2.18M
2026-08-315.51%0.0M0.5M2.05M
2026-08-141.37%0.0M2.6M2.08M
2026-07-310.25%0.0M2.6M1.62M
2026-07-154.68%0.0M0.3M1.44M
2026-06-3072.57%0.2M0.3M1.30M
2026-06-153.53%0.0M0.3M20.06K
2026-05-293.20%0.0M0.3M8.63K
2026-05-153.97%0.0M0.3M8.69K
2026-04-300.14%0.0M0.6M8.52K
2026-04-150.84%0.0M0.6M9.27K
2026-03-310.85%0.0M0.6M14.44K
2026-03-130.86%0.0M0.6M76.11K
2026-02-272.39%0.0M0.6M90.16K
2026-02-131.61%0.0M0.6M92.23K
2026-01-302.12%0.0M0.6M91.15K
2026-01-151.71%0.0M0.6M92.84K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-09EFFECTEffectiveness filing by commission orderSEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-09-29F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-09-036-K/A2026-09-03SEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-06-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-26SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-21SCHEDULE 13DSEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-04-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-16SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-02-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-11SEC
2026-01-2920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-09-30SEC
2026-01-07SCHEDULE 13G/ASEC
2025-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP2.68%
OSAIC HOLDINGS, INC.0.98%
GEODE CAPITAL MANAGEMENT, LLC0.89%
UBS Group AG0.03%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.93%

OakChart. UPC. Cached 15 minutes.

Some panels did not load: ratings, insider.